📰 Noah Berkowitz News
Noah Berkowitz News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Noah Berkowitz. Real-time updates on events, politics, business and more.
June 3, 2024
NEW HAVEN, Conn., June 03, 2024 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will...
May 16, 2024
Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.
May 2, 2024
NEW HAVEN, Conn., May 02, 2024 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will...
May 25, 2023
Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with... | May 25, 2023
May 25, 2023
Results from Phase 3 COMMANDS study, selected for ASCO's official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent
May 2, 2023
BMS is seeking approval of Reblozyl (lupatercept) as a first-line treatment of anemia in adults with lower-risk MDS.
May 2, 2023
The treatment showed significant improvement in patients in patients who require frequent blood transfusions and are at risk of infection.
May 1, 2023
Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an... | May 1, 2023
May 1, 2023
Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an erythropoiesis-stimulating agent in patients with very low/low/intermediate-risk MDSU.S. FDA has assigned a target action dat...
May 1, 2023
The FDA has granted a priority review to the supplemental biologics license application seeking to expand the current indication of luspatercep to include treatment of anemia in patients with very low- to intermediate-risk myelodysplastic syndrome who have not previously received erythropoiesis-stimulating agents and who may require red blood cell transfusions.